Clusterin Pharmaceuticals and Treatment Methods Using the Same

Abstract

Disclosed are pharmaceutical compositions comprising clusterin and polypeptides substantially the same as clusterin and treatment methods for inflammatory diseases and dry eye disease. The pharmaceutical compositions include an isolated clusterin or an isolated polypeptide substantially the same as clusterin. The clusterin is preferably secreted clusterin. The method of treating dry eye disease includes administering to a patient in need an effective amount of a pharmaceutical composition comprising an isolated clusterin or an isolated polypeptide substantially the same as clusterin. The method of treating a disease state characterized by inflammation includes administering to a patient having the disease state an amount of isolated clusterin or a protein substantially the same as clusterin effective to decrease the activity of a matrix metallproteinase selected from the group consisting of MMP-9, MMP-2 and MMP-7.

1 . A pharmaceutical composition comprising:
 an isolated clusterin or a polypeptide substantially the same as clusterin.   
     
     
         2 . The pharmaceutical composition of  claim 1 , wherein the clusterin is secreted clusterin. 
     
     
         3 . The pharmaceutical composition of  claim 1 , further comprising a carrier. 
     
     
         4 . The pharmaceutical composition of  claim 3 , wherein the carrier is a sterile solution. 
     
     
         5 . A method of treating dry eye disease comprising:
 administering to a patient in need thereof an effective amount of a pharmaceutical composition comprising an isolated clusterin or an isolated protein substantially the same as clusterin.   
     
     
         6 . The method of  claim 5 , wherein the pharmaceutical composition comprises secreted clusterin. 
     
     
         7 . The method of  claim 5 , wherein the administration is topical. 
     
     
         8 . The method of  claim 5 , wherein the pharmaceutical composition further comprises a liquid carrier, and administration is by contacting the pharmaceutical composition to the surface of an eye of the patient. 
     
     
         9 . A method for treating a disease state characterized by inflammation comprising:
 Administering to a patient having the disease state an amount of an isolated clusterin or a polypeptide substantially the same as clusterin effective to decrease the activity of selected from the group consisting of MMP-9, MMP-2, and MMP-7.   
     
     
         10 . The method of  claim 9 , wherein the MMP is MMP-9. 
     
     
         11 . The method of  claim 9 , wherein the MMP is MMP-2. 
     
     
         12 . The method of  claim 9 , wherein the MMP is MMP-7. 
     
     
         13 . The method of  claim 9 , wherein the disease state is selected from the group consisting of inflammatory lung disease, cancer, multiple sclerosis, Alzheimer's disease, artherosclerosis, airway inflammation, pulmonary fibrosis, glomerulonephritis, bacterial meningitis, uveroentinitis, graft-versus-host disease, emphysema, aortic aneurysm and restenosis after angioplasty as a treatment for atherosclerosis.